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ABSTRACT
Peripheral neuropathy (PN) is very prevalent in
cancer patients and a leading cause of pain
related to cancer. However, the underlying
pathophysiological mechanisms vary signifi-
cantly. Peripheral neuropathy can be a direct or
an indirect complication of cancer or
cancer-related treatment, or a pre-existing
comorbidity not related to cancer. PN might
also occur as a paraneoplastic neurological
syndrome. Such syndromes are immune-medi-
ated manifestations that usually precede the
diagnosis of cancer or cancer’s relapse. Pain is
very prevalent in paraneoplastic peripheral
neuropathies and, therefore, merits attention.
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INTRODUCTION
The term peripheral neuropathy (PN) refers to
any disorder of the peripheral nervous system
including single and multiple (asymmetric)
mononeuropathies, symmetrical involvement
of many nerves (polyneuropathy) or sole
involvement of the dorsal root ganglia [1, 2].
PN is very prevalent in cancer patients;
however the underlying pathophysiological
mechanisms vary significantly. PN can be a
direct or an indirect complication of cancer or
cancer-related treatment, or a pre-existing
comorbidity not related to cancer. Directly
cancer can cause single or multiple mononeu-
ropathies and plexopathy as a result of invasion
by cancer cells of the peripheral nerves and
plexus, respectively [3]. Indirectly, similar
pathologies might occur following iatrogenic
nerve and plexus injuries, either secondary to
radiotherapy or surgery [4]. Treatment-related
PN also includes chemotherapy-induced PN,
which is probably the most common cause of
PN in cancer [5].
However, PN in cancer might occur as a
paraneoplastic neurological syndrome (PNS).
PNS are a heterogeneous group of neurological
disorders triggered by cancer. To be considered
as paraneoplastic, the neurological syndrome
should occur within 5 years of cancer diagnosis
[6], though there are many reports of possible
PNS that have exceeded this time-frame [7]. PNS
are caused by mechanisms other than
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metastases, metabolic or nutritional deficits,
infections, coagulopathy, or side effects of can-
cer treatment such as chemotherapy. The dis-
covery that many PNS are associated with
antibodies against neural antigens expressed by
the tumour (antineural antibodies) has sug-
gested that PNS are immune-mediated [8].
Paraneoplastic PN is one of the commonest PNS
and often is a cause of neuropathic cancer pain
[9].
This editorial is an introduction to an
up-to-date systematic review and meta-analysis
of all published case reports or case series of
patients with paraneoplastic PN (doi:10.1007/
s40122-017-0076-3). The systematic review and
meta-analysis shed light onto both the clinical
and neurophysiological aspects, with a partic-
ular focus on pain as a manifestation of the
PNS.
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